NASDAQ:NVAX

Novavax - NVAX Stock Forecast, Price & News

$42.88

+0.58 (+1.37%)

(As of 08/16/2022 12:00 AM ET)

Add

Compare

Today's Range: $41.38
▼
$44.02
50-Day Range: $36.28
▼
$76.12
52-Week Range: $34.88
▼
$277.80

Volume: 4.89 million shs
Average Volume: 6.16 million shs
Market Capitalization: $3.35 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $151.00

Novavax MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 252.1% Upside
$151.00 Price Target
Short Interest: Healthy
20.90% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.27
Upright™ Environmental Score
News Sentiment: -0.09
Based on 27 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: -48.19%
From $20.98 to $10.87 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

363rd out of 1,124 stocks

Biological Products, Except Diagnostic Industry

58th out of 176 stocks

3.3

Analyst's Opinion

Consensus Rating
Novavax has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $151.00, Novavax has a forecasted upside of 252.1% from its current price of $42.88.
Amount of Analyst Coverage
Novavax has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
20.90% of the outstanding shares of Novavax have been sold short.
Short Interest Ratio / Days to Cover
Novavax has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Novavax has recently increased by 8.94%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Novavax does not currently pay a dividend.
Dividend Growth
Novavax does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Novavax has received a 76.16% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases ", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Novavax is -0.27.

2.2

News and Social Media Coverage

News Sentiment
Novavax has a news sentiment score of -0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 27 news articles for Novavax this week, compared to 19 articles on an average week.
Social Mentions This Week
MarketBeat has tracked 6 reddit mentions for Novavax this week, compared to 9 mentions on an average week.
Search Interest
184 people have searched for NVAX on MarketBeat in the last 30 days. This is an increase of 3% compared to the previous 30 days.
MarketBeat Follows
55 people have added Novavax to their MarketBeat watchlist in the last 30 days. This is an increase of 4% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Novavax insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.10% of the stock of Novavax is held by insiders.
Percentage Held by Institutions
43.91% of the stock of Novavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Novavax are expected to decrease by -48.19% in the coming year, from $20.98 to $10.87 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Novavax is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Novavax is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Novavax has a PEG Ratio of 0.05. PEG Ratios below 1 indicate that a company could be undervalued.

See Top Rated MarketRank™ Stocks Here

About Novavax (NASDAQ:NVAX) Stock

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Analyst Upgrades and Downgrades

NVAX has been the subject of several analyst reports. Bank of America began coverage on Novavax in a research note on Friday, May 20th. They issued an "underperform" rating and a $35.00 target price for the company. B. Riley reduced their price target on shares of Novavax from $181.00 to $171.00 in a research report on Friday, July 22nd. Cowen dropped their price objective on shares of Novavax to $110.00 in a research report on Monday. Cantor Fitzgerald lifted their target price on shares of Novavax from $146.00 to $168.00 in a report on Wednesday, June 8th. Finally, Cowen lowered their price target on Novavax from $150.00 to $110.00 and set an "outperform" rating for the company in a report on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Novavax presently has a consensus rating of "Hold" and an average target price of $151.00.

Novavax Stock Performance

Shares of NVAX Stock traded up $0.58 during mid-day trading on Tuesday, reaching $42.88. 4,885,391 shares of the company were exchanged, compared to its average volume of 6,156,194. The business's 50 day simple moving average is $52.67 and its 200 day simple moving average is $62.20. The company has a market capitalization of $3.35 billion, a P/E ratio of -2.20, a P/E/G ratio of 0.05 and a beta of 1.52. Novavax has a fifty-two week low of $34.88 and a fifty-two week high of $277.80.

Novavax (NASDAQ:NVAX - Get Rating) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($6.53) earnings per share for the quarter, missing the consensus estimate of $5.51 by ($12.04). The company had revenue of $186.00 million for the quarter, compared to analyst estimates of $1.02 billion. Novavax had a negative return on equity of 572.54% and a negative net margin of 114.32%. Novavax's revenue was down 37.6% on a year-over-year basis. During the same period in the prior year, the business earned ($4.75) earnings per share. On average, analysts forecast that Novavax will post 20.98 EPS for the current year.

Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

NVAX Stock News Headlines

July 19, 2022 | marketbeat.com

Is it Time to Cash Out Novavax Stock?

Vaccine developer Novavax (NASDAQ: NVAX) stock has collapsed (-61%) in 2022. The Company’s protein-based COVID-19 vaccine Nuvaxovid has launched in Europe and awaits CDC approval for launch the U.S.

August 16, 2022 | finance.yahoo.com

Novavax (NVAX) Seeks FDA Authorization for COVID-19 Booster Dose

August 16, 2022 | nasdaq.com

Novavax Submits EUA Application To FDA For COVID-19 Booster In Adults

August 16, 2022 | bizjournals.com

Novavax seeks FDA’s green light for Covid vaccine as a booster

August 16, 2022 | fool.com

Why Novavax Stock Eked Out a Gain Today - The Motley Fool

August 15, 2022 | fool.com

Why Novavax Stock Eked Out a Gain Today

August 15, 2022 | reuters.com

Novavax seeks U.S. authorization for COVID vaccine booster - Reuters.com

August 13, 2022 | nasdaq.com

South Korea Approves Novavax's Nuvaxovid COVID-19 Vaccine For Use In Adolescents - Nasdaq

August 13, 2022 | benzinga.com

Here's Why Novavax Stock Is Trading Higher - Benzinga

August 12, 2022 | seekingalpha.com

Novavax's COVID-19 shot gets approval for use in teenagers in South Korea - Seeking Alpha

August 11, 2022 | benzinga.com

Novavax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum - Benzinga

August 11, 2022 | finance.yahoo.com

These Analysts Just Made An Downgrade To Their Novavax, Inc. (NASDAQ:NVAX) EPS Forecasts

August 11, 2022 | finance.yahoo.com

Novavax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum

August 10, 2022 | nasdaq.com

1 Reason to Sell Novavax Stock, and 1 Reason to Buy - Nasdaq

August 10, 2022 | finance.yahoo.com

1 Reason to Sell Novavax Stock, and 1 Reason to Buy

August 10, 2022 | americanbankingnews.com

Novavax (NASDAQ:NVAX) Given New $110.00 Price Target at Cowen

August 10, 2022 | americanbankingnews.com

Novavax (NASDAQ:NVAX) Shares Gap Down After Earnings Miss

August 9, 2022 | marketwatch.com

China closes Tibet's Potala Palace over COVID outbreak, and Novavax stock is slammed by weak earnings and halving of sales guidance - MarketWatch

August 9, 2022 | seekingalpha.com

Why did Novavax stock plunge today? Q2 revenue miss, guidance cut - Seeking Alpha

August 9, 2022 | bloomberg.com

Novavax Rout Deepens to 87% From Peak After Covid-Shot Setbacks - Bloomberg

August 9, 2022 | businesswire.com

Nomi Health Adds Access to Novavax COVID Vaccine in Utah - Business Wire

August 9, 2022 | reuters.com

Novavax tumbles 30% as waning COVID-19 vaccine demand hits outlook - Reuters

August 9, 2022 | wsj.com

Poor Demand for Its Covid Vaccine Prompts Novavax to Cut Sales Forecast - The Wall Street Journal

August 9, 2022 | finance.yahoo.com

Novavax (NVAX) Q2 Earnings Miss, Cuts '22 Sales Guidance by Half

August 9, 2022 | finance.yahoo.com

Is Novavax A Sell After Its Quarterly Flop Led To A Guidance Cut?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

NVAX Company Calendar

Last Earnings: 8/08/2022
Today: 8/17/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:NVAX
CUSIP: 67000210
CIK: 1000694
Web: www.novavax.com
Phone: (240) 268-2000
Fax: 240-268-2100
Employees: 1,541
Year Founded: 1987

Price Target and Rating

Average Stock Price Forecast: $151.00
High Stock Price Forecast: $209.00
Low Stock Price Forecast: $35.00
Forecasted Upside/Downside: +252.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($19.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 2.04
P/E Growth: 0.05
Net Income: $-1,743,750,000.00
Net Margins: -114.32%
Pretax Margin: -112.25%
Return on Equity: -572.54%
Return on Assets: -55.69%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.99
Quick Ratio: 0.87

Sales & Book Value

Annual Sales: $1.15 billion
Price / Sales: 2.92
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($4.65) per share
Price / Book: -9.22

Miscellaneous

Outstanding Shares: 78,135,000
Free Float: 76,494,000
Market Cap: $3.35 billion
Optionable: Optionable
Beta: 1.52

Social Links

Key Executives

Mr. Stanley Charles Erck (Age 74)
Pres, CEO & Director
Comp: $1.12M
Mr. James Patrick Kelly C.F.A. (Age 56)
Exec. VP, CFO & Treasurer
Comp: $355.23k
Mr. John A. Herrmann III (Age 56)
Exec. VP, Chief Legal Officer & Corp. Sec.
Comp: $657.8k
Mr. John Joseph Trizzino B.S. (Age 62)
M.B.A., Exec. VP and Chief Bus. & Commercial Officer
Comp: $636.85k
Dr. Gregory M. Glenn (Age 68)
Pres of R&D
Comp: $813.44k
Mr. Richard P. Crowley (Age 65)
Exec. VP & COO
Dr. Gale E. Smith (Age 72)
Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist
Mr. Biegie Lee
Sr. VP & Chief Information Officer
Ms. Silvia Taylor M.B.A.
MBA, Sr. VP of Global Corp. Affairs & Investor Relations
Mr. Troy Morgan Esq. (Age 51)
J.D., Sr. VP & Chief Compliance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NVAX Stock - Frequently Asked Questions

Should I buy or sell Novavax stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NVAX shares.
View NVAX analyst ratings or view top-rated stocks.
What is Novavax's stock price forecast for 2022?: 8 Wall Street research analysts have issued 12-month target prices for Novavax's shares. Their NVAX share price forecasts range from $35.00 to $209.00. On average, they expect the company's share price to reach $151.00 in the next twelve months. This suggests a possible upside of 252.1% from the stock's current price.
View analysts price targets for NVAX or view top-rated stocks among Wall Street analysts.
How have NVAX shares performed in 2022?: Novavax's stock was trading at $143.07 on January 1st, 2022. Since then, NVAX stock has decreased by 70.0% and is now trading at $42.88.
View the best growth stocks for 2022 here.
When is Novavax's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NVAX earnings forecast.
How were Novavax's earnings last quarter?: Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings data on Monday, August, 8th. The biopharmaceutical company reported ($6.53) earnings per share for the quarter, missing the consensus estimate of $5.51 by $12.04. The biopharmaceutical company earned $186 million during the quarter, compared to analysts' expectations of $1.02 billion. Novavax had a negative trailing twelve-month return on equity of 572.54% and a negative net margin of 114.32%. The company's revenue for the quarter was down 37.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($4.75) EPS.
When did Novavax's stock split?: Shares of Novavax reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What guidance has Novavax issued on next quarter's earnings?: Novavax issued an update on its FY 2022 earnings guidance on Tuesday, August, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.00 billion-$2.30 billion, compared to the consensus revenue estimate of $4.27 billion.
What is Stanley C. Erck's approval rating as Novavax's CEO?: 46 employees have rated Novavax Chief Executive Officer Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among the company's employees.

What other stocks do shareholders of Novavax own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).
What is Novavax's stock symbol?: Novavax trades on the NASDAQ under the ticker symbol "NVAX."
Who are Novavax's major shareholders?: Novavax's stock is owned by a variety of retail and institutional investors. Top institutional investors include State Street Corp (3.80%), Citadel Advisors LLC (0.00%), Jane Street Group LLC (0.00%), JPMorgan Chase & Co. (0.00%), Group One Trading L.P. (0.00%) and Northern Trust Corp (0.45%). Insiders that own company stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends.
How do I buy shares of Novavax?: Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Novavax's stock price today?: One share of NVAX stock can currently be purchased for approximately $42.88.
How much money does Novavax make?: Novavax (NASDAQ:NVAX) has a market capitalization of $3.35 billion and generates $1.15 billion in revenue each year. The biopharmaceutical company earns $-1,743,750,000.00 in net income (profit) each year or ($19.46) on an earnings per share basis.
How many employees does Novavax have?: The company employs 1,541 workers across the globe.
When was Novavax founded?: Novavax was founded in 1987.
How can I contact Novavax?: Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for the company is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at ir@novavax.com, or via fax at 240-268-2100.

This page (NASDAQ:NVAX) was last updated on 8/17/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Novavax - NVAX Stock Forecast, Price & News

Novavax MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Social Mentions This Week

Search Interest

MarketBeat Follows